In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Circulating serum extracellular matrix degradation enzyme cathepsin S predicts mortality and improves risk stratification over the GRACE score in patients with non-ST elevation acute coronary syndrom

Session Non-troponin biomarkers in acute coronary syndromes

Speaker Kateryna Sopova

Event : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Abstract Sessions

Authors : K Sopova (Newcastle-Upon-Tyne,GB), G Georgiopoulos (Athens,GR), M Mueller-Hennessen (Heidelberg,DE), M Sachse (Frankfurt am Main,DE), N Vlachogiannis (Newcastle-Upon-Tyne,GB), C Bakogiannis (Newcastle-Upon-Tyne,GB), M Biener (Heidelberg,DE), M Vafaie (Heidelberg,DE), A Gatsiou (Newcastle-Upon-Tyne,GB), A Zaman (Newcastle upon Tyne,GB), H Katus (Heidelberg,DE), I Spyridopoulos (Newcastle-Upon-Tyne,GB), E Giannitsis (Heidelberg,DE), K Stamatelopoulos (Athens,GR), K Stellos (Newcastle-Upon-Tyne,GB)

Authors:
K Sopova1 , G Georgiopoulos2 , M Mueller-Hennessen3 , M Sachse4 , N Vlachogiannis1 , C Bakogiannis1 , M Biener3 , M Vafaie3 , A Gatsiou1 , A Zaman5 , H Katus3 , I Spyridopoulos1 , E Giannitsis3 , K Stamatelopoulos2 , K Stellos1 , 1Newcastle University - Newcastle Upon Tyne - United Kingdom of Great Britain & Northern Ireland , 2Alexandra University Hospital, Department of Clinical Therapeutics - Athens - Greece , 3University Hospital of Heidelberg, Department of Internal Medicine III, Cardiology - Heidelberg - Germany , 4Institute of Cardiovascular Regeneration, J.W. Goethe University Frankfurt - Frankfurt am Main - Germany , 5Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Trust and Institute of Cellular Medicine - Newcastle upon Tyne - United Kingdom of Great Britain & Northern Ireland ,

Citation:

Background Blood-based biomarkers may be useful in the identification of residual risk for death or acute myocardial infarction (AMI) in patients with a previous acute coronary syndrome. Cathepsin S (CTSS) is a lysosomal cysteine protease with potent elastolytic and collagenolytic activity, which plays an important role in cardiovascular disease through extracellular matrix degradation, vasa vasorum development and atherosclerotic plaque rupture. The aim of the present study was to determine the prognostic and reclassification value of baseline circulating levels of CTSS after adjustment for the Global Registry of Acute Coronary Events (GRACE) score, which is widely recommended for risk stratification in non-ST-segment elevation acute coronary syndrome (NSTE-ACS).

Methods CTSS was measured in blood samples collected from 1,129 consecutive patients with adjudicated NSTE-ACS presenting at an acute chest pain unit for evaluation of a possible acute coronary syndrome. Cardiovascular (CV) death and a composite of all-cause mortality and AMI were evaluated as the primary and secondary endpoints of the study, respectively.  The additive prognostic value of CTSS over the GRACE score was estimated by the Net Reclassification Index (NRI) that examines the net upward and downward reclassification into correct pre-defined risk categories.

Results After a median follow-up of 21 months, 101 (8.95%) deaths were reported, of which 63 (5.6%) were of cardiac origin. The combined endpoint occurred in 176 (15.6%) patients. Patients with CTSS in the highest tertile presented the greatest risk for all-cause mortality (HR=1.84 for highest versus lowest tertile of CTSS distribution, 95% CI 1.1-3.08, P=0.02) and CV death (HR=2.5 for highest versus lowest tertile of CTSS distribution, 95% CI 1.24-5.05, P=0.011) after adjustment for age, gender, diabetes mellitus, hs-cTnT, hsCRP, revascularization and index diagnosis. Similarly, CTSS was associated with increased risk of cardiovascular death after adjusting for the GRACE Score (adjusted HR for highest versus lowest tertile of CTSS distribution=2.34, 95% CI 1.18-4.64, P=0.015). Further, CTSS predicted the combined endpoint of all-cause death or non-fatal MI independently of the GRACE Score (adjusted HR for highest versus lowest tertile of CTSS distribution=1.67, 95% CI 1.15-2.42, P=0.007). When CTSS was added over the GRACE Score, it conferred significant reclassification value for CV death (NRI=21.4%, P=0.008). Similarly, CTSS correctly reclassified risk for all-cause death or non-fatal MI (P=0.006) in 15.9% of the population.

Conclusions Circulating CTSS predicts mortality and improves risk stratification of patients with NSTE-ACS over the GRACE score recommended by clinical guidelines. The clinical application of CTSS as a novel biomarker in NSTE-ACS should be further explored and validated.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are